OAKLAND PARK, FL / ACCESS Newswire / July 21, 2025 / EndoUVTech is a medical device innovator specializing in UV laser-based surgical technologies for blood clots in the brain, today announced that the United States Patent and Trademark Office has issued a fourth U.S. Patent, No. 12,357,383, titled "Device and Method for Dilation of a Tubular Anatomical Structure." This newly granted patent further strengthens EndoUVTech's growing intellectual property portfolio and global patent coverage.

The technology, developed by Dr. Brant Watson PhD introduces a minimally invasive approach for the controlled dilation of tubular anatomical structures. Its purpose is to improve procedural precision, reduce trauma to vessel walls, and enhance outcomes across a broad range of vascular and endovascular interventions.

"This patent underscores how we're redefining what's possible in vascular intervention," said Chip Van Vurst, CEO of Endo UV Tech, Inc. "We are focused on delivering practical innovations that solve real-world challenges for surgeons and patients alike, and this latest development reflects the depth and momentum of our work."

EndoUVTech remains on track to submit its lead device to the U.S. Food and Drug Administration (FDA) in Q4 2025. This planned submission represents a major step in the company's effort to bring UV laser-based tools to market, addressing critical unmet needs in vascular and neurovascular care.

About Endo UV Tech, Inc.

EndoUVtech is a medical device company headquartered in Oakland Park, Florida, dedicated to developing advanced technologies that improve outcomes for patients suffering from ischemic stroke (blood clots in the brain) and other cardiovascular conditions. Founded by a team of medical industry experts and scientists, the company focuses on UV-based devices that aim to reduce side effects and enhance recovery for ischemic stroke patients.

The company's flagship product, the "EndoSmartUV" Laser system, is designed to minimize tissue damage, improve clot removal during endovascular procedures, and dissolve downstream platelet clots that cause stroke side effects.

For more information, visit: www.endouvtech.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding potential product performance, anticipated regulatory approvals, and future market opportunities for EndoUVtech and its manufacturing partner. These statements are based on current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially from those projected.

Such risks and uncertainties include, but are not limited to, the timing and success of regulatory submissions and approvals, market acceptance of new products, manufacturing readiness, competition, intellectual property protection, and other factors. Endo UV Tech, Inc. undertakes no obligation to update forward-looking statements because of new information, future events, or otherwise, except as required by law.

Media Contact:
Lisa Goddard, Media Relations
Phone: (514) 817-5884
Email: lisa@EndoUVtech.com

Investor Inquiries:
Vincent Iantomasi, Investor Relations
Phone: (514) 947-4966
Email: vincent@EndoUVtech.com

SOURCE: EndoUVtech